|
Allon Therapeutics wants to make Alzheimer's disease nothing but a faded memory. The company's primary focus is on developing treatments for Alzheimer's and other neurodegenerative diseases that lead to memory loss and cognitive impairment. Its lead candidate AL-108 is a nasal spray that has shown some efficacy in clinical trials in treating the symptoms of patients with amnestic mild cognitive impairment, a precursor to Alzheimer's. Allon has collaborations with the National Institute on Aging, the Alzheimer's Disease Cooperative Study, the Institute for the Study of Aging, and the Tel Aviv University.
|
| | | Contact Information | |
Address: |
506-1168 Hamilton St.
Vancouver, British Columbia V6B 2S2, Canada
| | Phone: | 604-736-0634 | | Fax: | 604-736-1616 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.00 M |
|
|
Key People
| | • |
Chairman:
James J. (Jim) Miller
| | • |
President, CEO, and Secretary:
Gordon C. McCauley
| | • |
CFO:
Matthew J. Carlyle
|
|
|
